Table 2.
Baseline characteristics of the included patients.
| Characteristic | STAMPEDE-Doc* | STAMPEDE-Abi* | GETUG-AFU15 | CHAARTED | LATITUDE | ENZAMET | TITAN | ARCHES | ZAPCA | STAMPEDE-Bis* | STAMPEDE-Doc+Bis* | STAMPEDE-Cel* | STAMPEDE-Cel+Bis* | CALGB | MRC PR05 | STAMPEDE-Abi/Doc* | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | ADT | CT | Doc | Abi | |
| Median age (years) | 65 | 65 | 67 | 67 | 64 | 63 | 63 | 64 | 67 | 68 | 69 | 69.2 | 68 | 69 | 70 | 70 | 71.5 | 73 | 65 | 66 | 65 | 66 | 65 | 66 | 65 | 65 | 66.7 | 66.1 | 71 | 71 | 66 | 66 |
| Median PSA (ng/ml) | 67 | 70 | 56 | 51 | 25.8 | 26.7 | 52.1 | 50.9 | NA | NA | NA | NA | 4.02 | 5.97 | 5.1 | 5.4 | 375.2 | 328.0 | 67 | 59 | 67 | 63 | 67 | 57 | 67 | 70 | 6.8 | 6.9 | NA | NA | 58 | 55 |
| ECOG=0 | NA | NA | NA | NA | 96% | 99% | 69.2% | 69.8% | NA | NA | 72.1% | 71.9% | 66% | 62.5% | 76.9% | 78% | 70% | 67.9% | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| ECOG≥1 | NA | NA | NA | NA | 4% | 1% | 30.8% | 30.2% | NA | NA | 27.9% | 28.1% | 34% | 37.5% | 23.1% | 21.8% | 30% | 32.1% | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| T stage ≤ T2 | 13% | 10% | 10% | 9% | NA | NA | NA | NA | NA | NA | 29.1% | 26.3% | 26% | 35.8% | NA | NA | NA | NA | 13% | 11% | 13% | 12% | 12% | 8% | 12% | 13% | NA | NA | NA | NA | 13% | 10% |
| T stage≥T3 | 82% | 84% | 85% | 86% | NA | NA | NA | NA | NA | NA | 45.9% | 50.6% | 62.6% | 54.5% | NA | NA | NA | NA | 82% | 83% | 82% | 80% | 81% | 84% | 81% | 81% | NA | NA | NA | NA | 85% | 84% |
| N stage=N0 | 44% | 44% | 46% | 45% | NA | NA | NA | NA | NA | NA | 42.2% | 40.1% | 41% | 40.4% | NA | NA | NA | NA | 44% | 44% | 44% | 45% | 45% | 46% | 45% | 45% | NA | NA | NA | NA | 44% | 42% |
| N stage=N1 | 50% | 50% | 50% | 50% | NA | NA | NA | NA | NA | NA | 34.5% | 36.4% | 34.9% | 37.9% | NA | NA | NA | NA | 50% | 51% | 50% | 49% | 49% | 47% | 49% | 48% | NA | NA | NA | NA | 52% | 54% |
| Visceral metastases | 4% | 5% | 3% | 3% | 12% | 15% | 16.8% | 14.4% | 19% | 20% | 12% | 11% | 14.6% | 11.3% | 49.6% | 46.7% | NA | NA | 4% | 5% | 4% | 4% | 4% | 3% | 4% | 6% | 6% | 7% | NA | NA | NA | NA |
| GS <8 | 24% | 19% | 23% | 23% | 41% | 45% | 26.4% | 29.5% | 2.2% | 2.7% | 29% | 27% | 32.1% | 33.1% | 32.5% | 29.8% | 16.4% | 19.3% | 24% | 21% | 24% | 20% | 25% | 26% | 25% | 27% | 36% | 39% | NA | NA | 19% | 25% |
| GS≥8 | 68% | 74% | 75% | 74% | 59% | 55% | 61.8% | 60.7% | 97% | 98% | 57% | 60% | 67.9% | 66.9% | 64.8% | 67.2% | 83.6% | 80.7% | 68% | 71% | 68% | 72% | 66% | 65% | 66% | 62% | 58% | 58% | NA | NA | 81% | 75% |
| Low volume | NA | NA | NA | NA | 53% | 52% | 36.4% | 33.8% | NA | NA | 47% | 48% | 36.4% | 38.1% | 35.2% | 38.3% | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| High volume | NA | NA | NA | NA | 47% | 48% | 63.6% | 66.2% | NA | NA | 53% | 52% | 63.6% | 61.9% | 64.8% | 61.7% | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Doc, docetaxel; Abi, abiraterone; Bis, bisphosphonate; Cel, celecoxib; ADT, androgen-deprivation therapy; CT, combination therapy; PSA, prostate-specific antigen; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score.
*
Data of overall population were used.